Basic Information
| LncRNA/CircRNA Name | CCND2-AS1 |
| Synonyms | NA |
| Region | GRCh38_12:4248765-4276184 |
| Ensemble | ENSG00000255920 |
| Refseq | NR_125790 |
Classification Information
| Regulatory Mechanism | Biological Function | Clinical Application | |||
|---|---|---|---|---|---|
| TF | Immune | Survival | |||
| Enhancer | Apoptosis | Drug | |||
| Variant | Cell Growth | Circulating | |||
| MiRNA | EMT | Metastasis | |||
| Methylation | Coding Ability | Recurrence |
Cancer&Entry Information
| Cancer Name | glioma |
| ICD-0-3 | NA |
| Methods | qPCR, RNAi, Western blot, Luciferase reporter assay etc. |
| Sample | glioma tissues, cell lines (U87, U251, HA) |
| Expression Pattern | up-regulated |
| Function Description | We found that lncRNA CCND2-AS2 is significantly up regulated in malignant glioma tissues and cell lines. Both loss- and gain-functions assays show that CCND2-AS1 promotes glioma cells proliferation and growth. In addition, we also revealed that highly expressed CCND2-AS1 could enhance Wnt/B-catenin signaling in glioma. |
| Pubmed ID | 27923660 |
| Year | 2017 |
| Title | Highly expressed lncRNA CCND2-AS1 promotes glioma cell proliferation through Wnt/B-catenin signaling. |
External Links
| Links for CCND2-AS1 | GenBank HGNC NONCODE |
| Links for glioma | OMIM COSMIC |